CRISPR/Cas9-mediated introduction of the sodium/iodide symporter gene enables noninvasive in vivo tracking of induced pluripotent stem cell-derived cardiomyocytes

John W. Ostrominski(Brigham and Women's Hospital), Cynthia E. Dunbar(National Institutes of Health), Mark C. Haigney(Uniformed Services University of the Health Sciences), Hong San(National Institutes of Health), Noriko Sato(National Cancer Institute), Manfred Boehm(National Heart Lung and Blood Institute), Yongshun Lin(University of Michigan–Ann Arbor), Falguni Basuli, Racquel Valadez(Center for Cancer Research), So Gun Hong(National Institutes of Health), Rolf E. Swenson, Dakshesh Patel(United States Food and Drug Administration), Kah-Whye Peng(Mayo Clinic), Ksenia Blinova(United States Food and Drug Administration), Ravi Chandra Yada(National Institutes of Health), Peter L. Choyke(National Cancer Institute), Xiang Zhang(First Affiliated Hospital of Wenzhou Medical University), Michael G. Klein(Uniformed Services University of the Health Sciences), Jizhong Zou(National Institute of Arthritis and Musculoskeletal and Skin Diseases), Maryknoll Palisoc(Center for Cancer Research), Stefania Pittaluga(Cancer Institute (WIA))
Stem Cells Translational Medicine
July 23, 2020
Cited by 16


Related Papers